BMT-CTN is paying for 80% of the aGVHD trial
@Fastback6666 I'm not sure that is the case .... well it is not what it says in the original GVHD trial notification and / or today's HY Report (see below extract) ?
It is my understanding that the costs will be shared by BMT CTN and Mesoblast, but I don't recall seeing confirmation that BMT CTN are contributing 80% of the total costs ? If the 80% figure you are quoting is from the ASX announcements below, then I am not sure you are reading it right because that isn't what it says ? It says BMT CTN centers are responsible for approximately 80% of all US allogeneic bone marrow transplants (BMTs) not 80% of the upcoming Mesoblast sr-GVHD trial costs ?
" Blood and Marrow Transplant Clinical Trials Network (BMT CTN), a body including centers responsible for approximately 80% of all US allogeneic BMTs, "
Happy for you to show me where you got this 80% figure from if it is from somewhere else and it is the case that BMT CTN are paying this large percentage of costs ?
From today's HY Report:
Ann: Half Year Report and Accounts (including Appendix 4D), page-16
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.22%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.09 | $4.781M | 4.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 356702 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 3365 | 3 |
View Market Depth
| Last trade - 13.40pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |